Your browser is no longer supported. Please, upgrade your browser.
Settings
ATRA Atara Biotherapeutics, Inc. daily Stock Chart
ATRA [NASD]
Atara Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-3.47 Insider Own5.70% Shs Outstand29.77M Perf Week45.99%
Market Cap841.00M Forward P/E- EPS next Y-4.66 Insider Trans-11.55% Shs Float26.02M Perf Month94.16%
Income-102.40M PEG- EPS next Q-1.14 Inst Own- Short Float19.12% Perf Quarter94.16%
Sales- P/S- EPS this Y-23.00% Inst Trans0.03% Short Ratio9.54 Perf Half Y78.23%
Book/sh6.76 P/B4.18 EPS next Y-17.40% ROA-41.80% Target Price29.60 Perf Year101.79%
Cash/sh6.72 P/C4.20 EPS next 5Y- ROE-44.80% 52W Range11.80 - 30.90 Perf YTD56.08%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.58% Beta-
Dividend %- Quick Ratio12.50 Sales past 5Y- Gross Margin- 52W Low139.41% ATR1.92
Employees96 Current Ratio12.50 Sales Q/Q- Oper. Margin- RSI (14)86.62 Volatility14.51% 9.38%
OptionableYes Debt/Eq0.00 EPS Q/Q-15.80% Profit Margin- Rel Volume3.45 Prev Close27.55
ShortableYes LT Debt/Eq0.00 EarningsFeb 08 AMC Payout- Avg Volume521.19K Price28.25
Recom1.80 SMA2054.82% SMA5077.43% SMA20083.31% Volume1,709,929 Change2.54%
Jan-03-18Upgrade Citigroup Sell → Neutral
Oct-06-17Resumed Goldman Neutral
Jun-22-17Resumed Jefferies Buy $30
Oct-24-16Resumed Jefferies Buy
Sep-15-16Downgrade Goldman Neutral → Sell
Dec-15-15Downgrade Citigroup Buy → Sell
Nov-18-15Resumed Goldman Neutral
Sep-25-15Initiated JMP Securities Mkt Perform
Sep-09-15Initiated Canaccord Genuity Buy $80
Jun-04-15Reiterated Jefferies Buy $43 → $47
Jan-17-18 06:10AM  Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18) TheStreet.com
Jan-16-18 07:36PM  Winners & losers from JP Morgan Healthcare Conference CNBC Videos
06:59PM  Cramer reveals the biggest winners and losers from the JP... CNBC Videos
07:19AM  Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics Zacks
Jan-15-18 08:53AM  3 Stocks in Focus on New Analyst Coverage Zacks
Jan-12-18 03:00AM  Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily +27.54%
Jan-10-18 08:00AM  Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis GlobeNewswire +6.98%
Jan-04-18 04:15PM  Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire -6.49%
Jan-03-18 10:55PM  Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +6.35%
Jan-02-18 04:01PM  Atara Biotherapeutics Announces Proposed Offering of Common Stock GlobeNewswire
08:00AM  Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) GlobeNewswire
Dec-29-17 04:33PM  Why SandRidge Energy, Atara Biotherapeutics, and Hovnanian Enterprises Jumped Today Motley Fool +18.69%
03:28PM  Why Atara Biotherapeutics Stock Is Bolting Higher Today Motley Fool
11:35AM  Atara Biotherapeutics Wins FDA Clearance for Late-Stage Trials 24/7 Wall St.
06:00AM  Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) GlobeNewswire
Dec-28-17 06:30PM  Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST GlobeNewswire
Dec-27-17 01:24PM  [$$] Celgene: Two Small-Cap Biotech Stocks It's Selling Barrons.com
Dec-18-17 02:21PM  [$$] Morgan Stanley: Three Stocks It's Buying Now Barrons.com
Dec-11-17 10:00AM  Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD) GlobeNewswire
Nov-09-17 09:02AM  Atara Biotherapeutics reports 3Q loss Associated Press -8.01%
08:00AM  Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Nov-07-17 08:00AM  Atara Biotherapeutics to Participate in Four Upcoming Investor Conferences GlobeNewswire -6.50%
Nov-02-17 11:12AM  What Is Atara Biotherapeutics Incs (ATRA) Share Price Doing? Simply Wall St.
Nov-01-17 09:00AM  Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers GlobeNewswire
Oct-26-17 08:00AM  Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection GlobeNewswire
Oct-25-17 08:00AM  Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 GlobeNewswire -5.33%
Oct-19-17 08:00AM  Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS) GlobeNewswire
Oct-16-17 08:00AM  Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire
Sep-16-17 06:13PM  Should You Buy Atara Biotherapeutics Inc (ATRA) Now? Simply Wall St.
Sep-11-17 08:00AM  Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 GlobeNewswire
Sep-05-17 08:00AM  Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230 GlobeNewswire
Aug-31-17 04:15PM  Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire +7.14%
Aug-25-17 07:50AM  Featured Company News Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South Korea ACCESSWIRE
Aug-22-17 04:35PM  Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer GlobeNewswire
Aug-07-17 11:37PM  Atara Biotherapeutics reports 2Q loss Associated Press
06:36PM  Atara Biotherapeutics reports 2Q loss Associated Press
04:05PM  Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Aug-02-17 08:00AM  Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Jul-31-17 08:10AM  Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire
May-24-17 08:00AM  Atara Biotherapeutics to Present at Three Upcoming Investor Conferences GlobeNewswire -5.54%
May-10-17 05:00PM  Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team GlobeNewswire
May-05-17 05:02AM  Atara Biotherapeutics reports 1Q loss Associated Press -6.27%
May-04-17 04:15PM  Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Apr-21-17 09:34AM  Biotech Movers: XBiotech, Atara, Bellicum TheStreet.com -10.58%
08:00AM  Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC) GlobeNewswire
Apr-20-17 05:16PM  Atara Biotherapeutics shares rise on MS drug study results MarketWatch
04:20PM  Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 GlobeNewswire
Apr-03-17 08:00AM  Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer GlobeNewswire
Mar-27-17 05:08PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
Mar-17-17 12:45PM  Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire +7.51%
Mar-14-17 01:04PM  ATARA BIOTHERAPEUTICS, INC. Financials -11.01%
Mar-09-17 08:34AM  Atara Biotherapeutics reports 4Q loss Associated Press +8.38%
08:16AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights GlobeNewswire
Feb-10-17 04:13PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -6.52%
Feb-07-17 10:26AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-04-17 08:00AM  Atara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-17 08:00AM  Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E GlobeNewswire +6.16%
Dec-15-16 02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group Insider Monkey
02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group at Insider Monkey
Dec-14-16 06:15AM  Atara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock? Insider Monkey -13.02%
06:15AM  Atara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-12-16 08:00AM  Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Se GlobeNewswire
Dec-03-16 10:30AM  Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 GlobeNewswire
Nov-28-16 02:21PM  Atara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-04-16 08:28AM  Atara Biotherapeutics reports 3Q loss +6.32%
08:16AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Nov-03-16 09:00AM  Atara Bio's Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 GlobeNewswire
Nov-02-16 09:08AM  Atara Biotherapeutics (ATRA): Moving Average Crossover Alert
Oct-27-16 09:53AM  What Falling Estimates & Price Mean for Atara Biotherapeutics (ATRA)
Oct-18-16 08:00AM  Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) GlobeNewswire
Oct-11-16 08:00AM  Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems GlobeNewswire
Sep-29-16 06:00AM  'Mad Money' Lightning Round: Buy Red-Hot Suncoke Energy -5.27%
Sep-28-16 07:15PM  Cramer: If you're looking to invest in coal, here's my top pick at CNBC
Sep-23-16 05:17PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-15-16 07:56AM  Atara Biotherapeutics Has 25% Downside -10.08%
06:13AM  Atara Biotherapeutics downgraded by Goldman
Sep-13-16 03:23PM  Atara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016
Sep-08-16 04:05PM  Atara Bio to Participate in the Morgan Stanley Global Healthcare Conference GlobeNewswire
Aug-08-16 04:51PM  A Handful of Biotech Stocks Plunge After Disappointing Results Benzinga -9.37%
08:07AM  Atara Biotherapeutics reports 2Q loss
08:06AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Aug-04-16 04:05PM  Atara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference GlobeNewswire
Jul-18-16 08:00AM  AMAG Pharmaceuticals CEO William Heiden Elected to PhRMA Board of Directors GlobeNewswire
Jul-12-16 08:00AM  Atara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders GlobeNewswire
Jun-24-16 04:32PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-23-16 09:30AM  Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) GlobeNewswire
Jun-15-16 04:05PM  Atara Bio to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-06-16 06:30PM  Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate GlobeNewswire +6.49%
Jun-03-16 07:12AM  Biotech picks: ALDR & RDHE -5.02%
Jun-02-16 12:58PM  Atara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 +5.75%
May-31-16 04:05PM  Atara Bio to Present at Three Upcoming Investor Conferences GlobeNewswire
May-18-16 07:25PM  UPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
05:00PM  Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-09-16 08:00AM  Atara Bios Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress GlobeNewswire +8.85%
May-06-16 04:53PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCGRATH JOHNEVP & Chief Financial OfficerJan 12Option Exercise11.0030,000330,000123,154Jan 12 07:56 PM
Ciechanover Isaac E.Chief Executive OfficerJan 12Sale30.051003,005360,078Jan 12 07:55 PM
MCGRATH JOHNEVP & Chief Financial OfficerJan 12Sale24.7233,500828,12089,654Jan 12 07:56 PM
MCGRATH JOHNEVP & Chief Financial OfficerJan 11Sale20.773,50072,69593,154Jan 12 07:56 PM
Ciechanover Isaac E.Chief Executive OfficerJan 11Sale21.9520,000438,900360,178Jan 12 07:55 PM
Ciechanover Isaac E.Chief Executive OfficerJan 10Sale19.998,600171,938380,178Jan 12 07:55 PM
MCGRATH JOHNEVP & Chief Financial OfficerDec 29Sale20.0032,000640,00096,654Jan 02 07:14 PM
Ciechanover Isaac E.Chief Executive OfficerDec 29Sale18.6320,000372,628388,778Jan 02 07:12 PM
Ciechanover Isaac E.Chief Executive OfficerDec 28Sale15.152,20033,330408,778Jan 02 07:12 PM
Ciechanover Isaac E.Chief Executive OfficerDec 13Sale14.732,20032,406410,978Dec 14 05:34 PM
Ciechanover Isaac E.Chief Executive OfficerDec 12Sale14.562,20032,032413,178Dec 14 05:34 PM
Ciechanover Isaac E.Chief Executive OfficerNov 30Sale14.402,20031,680415,378Dec 01 04:37 PM
Ciechanover Isaac E.Chief Executive OfficerNov 29Sale14.092,20030,998417,578Dec 01 04:37 PM
Soffer GadEVP & Chief Strategy OfficerNov 17Sale15.007,000105,000256,236Nov 17 06:49 PM
Gallagher Carol GiltnerDirectorNov 16Sale14.201,18416,813109,738Nov 17 06:24 PM
Clark Mitchall G.EVP & Chief R & QA OfficerNov 16Sale14.203,29046,718163,052Nov 17 06:26 PM
Clark Mitchall G.EVP & Chief R & QA OfficerNov 15Option Exercise0.007,2120166,342Nov 17 06:26 PM
Ciechanover Isaac E.Chief Executive OfficerNov 15Option Exercise0.005,9080743,675Nov 17 06:26 PM
MCGRATH JOHNEVP & Chief Financial OfficerNov 15Option Exercise0.007,6970128,654Nov 17 06:24 PM
Fust Matthew KDirectorNov 15Option Exercise0.001,602030,503Nov 17 06:25 PM
Gallagher Carol GiltnerDirectorNov 15Option Exercise0.002,3660110,922Nov 17 06:24 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfNov 15Option Exercise0.008290344,134Nov 17 06:27 PM
Soffer GadEVP & Chief Strategy OfficerNov 15Option Exercise0.004,1460263,236Nov 17 06:49 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfNov 15Sale13.361,60421,429342,530Nov 17 06:27 PM
Ciechanover Isaac E.Chief Executive OfficerNov 14Sale13.412,20029,502419,778Nov 14 08:31 PM
Ciechanover Isaac E.Chief Executive OfficerNov 13Sale13.532,20029,766421,978Nov 14 08:31 PM
Ciechanover Isaac E.Chief Executive OfficerOct 27Sale13.602,20029,920424,178Oct 30 04:17 PM
Ciechanover Isaac E.Chief Executive OfficerOct 26Sale13.572,20029,854426,378Oct 30 04:17 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfOct 16Sale14.356,00086,100343,305Oct 17 04:46 PM
Ciechanover Isaac E.Chief Executive OfficerOct 12Sale14.782,20032,516428,578Oct 12 07:55 PM
Ciechanover Isaac E.Chief Executive OfficerOct 11Sale15.252,20033,550430,778Oct 12 07:55 PM
Ciechanover Isaac E.Chief Executive OfficerSep 20Sale15.562,20034,232432,978Sep 21 04:05 PM
Ciechanover Isaac E.Chief Executive OfficerSep 19Sale15.512,20034,122435,178Sep 21 04:05 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfSep 15Sale15.306,00091,800349,305Sep 18 05:46 PM
Ciechanover Isaac E.Chief Executive OfficerSep 07Sale14.982,20032,956437,378Sep 08 04:02 PM
Ciechanover Isaac E.Chief Executive OfficerSep 06Sale15.052,20033,110439,578Sep 08 04:02 PM
Ciechanover Isaac E.Chief Executive OfficerAug 23Sale13.512,20029,722441,778Aug 24 05:10 PM
Ciechanover Isaac E.Chief Executive OfficerAug 22Sale13.562,20029,832443,978Aug 24 05:10 PM
Soffer GadEVP & Chief Strategy OfficerAug 16Sale14.532,46435,802259,090Aug 17 05:37 PM
Gallagher Carol GiltnerDirectorAug 16Sale14.301,18416,931108,556Aug 17 05:38 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 16Sale14.392,10030,219120,957Aug 17 05:36 PM
Clark Mitchall G.EVP & Chief R & QA OfficerAug 16Sale14.333,02143,291159,130Aug 17 05:34 PM
Fust Matthew KDirectorAug 15Option Exercise0.001,603028,901Aug 17 05:41 PM
Clark Mitchall G.EVP & Chief R & QA OfficerAug 15Option Exercise0.007,2110162,151Aug 17 05:34 PM
Ciechanover Isaac E.Chief Executive OfficerAug 15Option Exercise0.005,9080737,767Aug 17 05:34 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 15Option Exercise0.007,6970125,157Aug 17 05:36 PM
Soffer GadEVP & Chief Strategy OfficerAug 15Option Exercise0.004,1450261,554Aug 17 05:37 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfAug 15Option Exercise0.008290362,909Aug 17 05:35 PM
Gallagher Carol GiltnerDirectorAug 15Option Exercise0.002,3660109,740Aug 17 05:38 PM
Soffer GadEVP & Chief Strategy OfficerAug 15Sale15.007,000105,000257,409Aug 17 05:37 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 15Sale14.232,10029,883123,057Aug 17 05:36 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfAug 15Sale14.757,604112,159355,305Aug 17 05:35 PM
Ciechanover Isaac E.Chief Executive OfficerAug 11Sale14.582,20032,076446,178Aug 14 07:23 PM
Ciechanover Isaac E.Chief Executive OfficerAug 10Sale14.752,20032,450448,378Aug 14 07:23 PM
Ciechanover Isaac E.Chief Executive OfficerJul 25Sale16.032,70043,283450,578Jul 26 04:52 PM
Ciechanover Isaac E.Chief Executive OfficerJul 24Sale16.942,80047,421453,278Jul 26 04:52 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfJul 17Sale14.926,00089,520362,080Jul 18 04:24 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfJun 15Sale12.656,00075,900368,080Jun 16 04:47 PM
Gallagher Carol GiltnerDirectorJun 09Sale13.151,00013,150107,374Jun 12 05:29 PM
Ciechanover Isaac E.Chief Executive OfficerMay 31Sale13.263,45045,747456,078May 31 07:44 PM
Ciechanover Isaac E.Chief Executive OfficerMay 30Sale13.443,45046,368459,528May 31 07:44 PM
Ciechanover Isaac E.Chief Executive OfficerMay 18Sale14.942,40035,856462,978May 19 04:05 PM
Ciechanover Isaac E.Chief Executive OfficerMay 17Sale14.882,40035,712465,378May 19 04:05 PM
MCGRATH JOHNEVP & Chief Financial OfficerMay 16Sale15.272,00030,540117,460May 17 05:01 PM
Gallagher Carol GiltnerDirectorMay 16Sale15.251,18418,056103,374May 17 05:01 PM
Soffer GadEVP & Chief Strategy OfficerMay 16Sale15.195,67486,188264,409May 17 04:56 PM
Clark Mitchall G.EVP & Chief R & QA OfficerMay 16Sale15.253,87359,063153,000May 17 04:57 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfMay 15Option Exercise0.008290381,684May 17 04:58 PM
Soffer GadEVP & Chief Strategy OfficerMay 15Option Exercise0.0010,5560270,083May 17 04:56 PM
Clark Mitchall G.EVP & Chief R & QA OfficerMay 15Option Exercise0.007,2120156,873May 17 04:57 PM
MCGRATH JOHNEVP & Chief Financial OfficerMay 15Option Exercise0.008,6330121,460May 17 05:01 PM
Fust Matthew KDirectorMay 15Option Exercise0.001,602022,298May 17 05:00 PM
Ciechanover Isaac E.Chief Executive OfficerMay 15Option Exercise0.005,9080731,859May 17 04:59 PM
Gallagher Carol GiltnerDirectorMay 15Option Exercise0.002,3660104,558May 17 05:01 PM
MCGRATH JOHNEVP & Chief Financial OfficerMay 15Sale14.952,00029,900119,460May 17 05:01 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfMay 15Sale14.997,604113,984374,080May 17 04:58 PM
Soffer GadEVP & Chief Strategy OfficerMay 15Sale15.137,000105,910259,527May 17 04:56 PM
Ciechanover Isaac E.Chief Executive OfficerApr 26Sale17.783,60064,008467,778Apr 26 07:34 PM
Ciechanover Isaac E.Chief Executive OfficerApr 25Sale17.333,60062,397471,378Apr 26 07:34 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfApr 17Sale17.286,000103,680380,855Apr 19 04:29 PM
Ciechanover Isaac E.Chief Executive OfficerApr 11Sale16.994,20071,358474,978Apr 12 04:20 PM
Ciechanover Isaac E.Chief Executive OfficerApr 10Sale17.083,00051,240479,178Apr 12 04:20 PM
Ciechanover Isaac E.Chief Executive OfficerMar 28Sale19.093,60068,728482,178Mar 28 08:13 PM
Ciechanover Isaac E.Chief Executive OfficerMar 27Sale20.3412,400252,216485,778Mar 28 08:13 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 23Sale21.086,500137,020112,827Mar 23 08:06 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 22Sale20.277,500152,025119,327Mar 23 08:06 PM
Ciechanover Isaac E.Chief Executive OfficerMar 17Sale19.8320,000396,576498,178Mar 20 06:50 PM
Ciechanover Isaac E.Chief Executive OfficerMar 16Sale18.5410,800200,232518,178Mar 20 06:50 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfMar 15Sale19.606,000117,600386,855Mar 17 05:07 PM
Soffer GadEVP & Chief Strategy OfficerMar 10Sale20.002,50050,000266,527Mar 13 05:42 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 10Sale20.0024,000480,000126,827Mar 10 07:57 PM
MCGRATH JOHNEVP & Chief Financial OfficerFeb 21Sale15.149,000136,260150,827Feb 22 05:32 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 16Sale15.572,40037,368348,978Feb 16 08:08 PM
Gallagher Carol GiltnerDirectorFeb 16Sale16.101,18319,046102,192Feb 16 08:12 PM
Soffer GadEVP & Chief Strategy OfficerFeb 16Sale15.627,273113,604269,027Feb 16 08:10 PM
Clark Mitchall G.EVP & Chief R & QA OfficerFeb 16Sale15.963,05948,822149,661Feb 16 08:09 PM
Clark Mitchall G.EVP & Chief R & QA OfficerFeb 15Option Exercise0.007,2110152,720Feb 16 08:09 PM
Soffer GadEVP & Chief Strategy OfficerFeb 15Option Exercise0.0013,7620276,300Feb 16 08:10 PM
Gallagher Carol GiltnerDirectorFeb 15Option Exercise0.002,3650103,375Feb 16 08:12 PM
Fust Matthew KDirectorFeb 15Option Exercise0.001,603020,696Feb 16 08:10 PM